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Summary 
A major obstacle to the effective use of adoptive immunotherapeutic  treatment of cancer is the 
difficulty of obtaining tumor-reactive lymphocytes in either sufficient numbers or with appropriate 
in vivo function to make such an approach feasible.  Previous studies have shown that antitumor 
cytotoxic T  lymphocytes (CTL) with in vivo efficacy can be generated in vitro from lymphoid 
cells obtained from lymph nodes that  drain  the anatomical  site of a tumor.  Results presented 
here demonstrate  that  inclusion of interleukin  7 (IL-7) into  the medium in which such CTL 
are cultured can support their growth in vitro for prolonged periods of time in the absence of 
repeated stimulation  with either tumor stimulator cells or tumor antigen.  More importantly, 
antitumor CTL propagated in medium containing IL-7 have retained both their antigenic specificity 
and their ability to reject tumors in vivo subsequent to intravenous injection.  Parallel  cultures 
of antitumor CTL similarly cultured in medium containing only IL-2 could only be maintained 
for 5-6 wk, after which the number and proportion of viable cells that were recoverable from 
such cultures progressively decreased. Phenotypic analysis of CTL maintained after extended culture 
(i.e.,  22 mo) in medium containing  IL-7 demonstrated them to be CD3+4-8 § T  cells. These 
cells were also found to express lymphocyte function associated 1, intercellular adhesion molecule 
1, and Mel-14 cell interaction molecules. The data also demonstrate that these CTL do not require 
the presence of antigen-presenting  cell populations to mount a proliferative response to tumor 
stimulator cells. Cells in these cultures were also demonstrated to produce IL-2 after stimulation 
with irradiated tumor cells, thereby indicating that these CTL have become independent of the 
requirement for CD4 § helper cells to survive and function either in vitro or in vivo. Collectively, 
the findings  that  IL-7 can beneficially augment  the generation,  and propagate  the long-term 
growth, of antitumor CTL from lymph nodes draining  a tumor site may have profound implications 
for promoting  the immunotherapeutic  treatment  of cancer in humans. 
A  major  obstacle  to  the  effective use  of adoptive  im- 
munotherapeutic  treatment  of cancer is the difficulty 
of obtaining tumor-reactive lymphocytes in either sufficient 
numbers or with appropriate in vivo function to make such 
an approach feasible. Experimental attempts in murine systems 
to solve these problems have included the use of donors ac- 
tively immunized with either irradiated tumor cells or tumor 
cells mixed with potent adjuvants as sources of primed tumor- 
reactive lymphoid cells for expansion in vitro (1-9).  How- 
ever, in the human situation, the luxury of syngeneic donors 
who can be immunized  and from whom tumor-reactive T 
cells  can be  obtained  and  propagated  for  subsequent  im- 
munotherapeutic  use does not  exist. 
The observation that solid tumor masses are often infiltrated 
by T cells (10-12) suggested the possibility that such tumor- 
infiltrating  lymphocytes  (TIL) 1  might  be  enriched  for 
tumor-reactive T cells that could be expanded in vitro using 
recombinant cytokines such as IL-2 (13-18). However, even 
short-term  culture  of tumor-reactive  T  cells  in  growth- 
promoting  concentrations  of IL-2 enhances the generation 
ofT cells that are dependent upon exogenous IL-2 for growth 
and survival in vitro and optimal function in vivo. Results 
from several studies have demonstrated the need for contin- 
uing treatment of the recipients with IL-2 after the infusion 
of antitumor effector cells in order to promote optimal func- 
tion in vivo (7,  8,  19-22).  As has previously been shown, 
1 Abbreviations used in this  paper:  DLN, draining lymph node; HSA, heat 
stable antigen; ICAM-1, intercellular adhesion molecule 1; TIL, tumor- 
infiltrating lymphocyte. 
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ation  and  effector function of transferred TIL can lead to 
significant toxicity. Further, even when using cultured TIL 
as a source of tumor-reactive lymphocytes it has been esti- 
mated that >2  x  1011 cells would be required to effectively 
treat patients with metastatic disease (23). These deficiencies 
continue to provide a major impetus  for the development 
of techniques  to enhance the in vivo efficacy of antitumor 
CTL generated in vitro. 
LN that drain the anatomical site of a tumor contain in- 
creased numbers of lymphocytes, and these cells can differen- 
tiate into antitumor CTL during a short in vitro culture period 
(24, 25). We have previously demonstrated that intravenous 
injection  of relatively modest numbers  of antitumor  CTL 
generated from such draining lymph nodes (DLN) are able 
to mediate tumor rejection in a systemic fashion and do not 
require ancillary cytokine treatment in order to perform this 
function  (26).  In addition,  we have recently evaluated the 
effects of a number of cytokines and combinations of cytokines 
to  augment  the generation  of therapeutically effective an- 
titumor  CTL  from  these DLN.  In  this  regard,  IL-7 was 
demonstrated to be substantially more potent than either IL-2 
or  IL-4 (27). 
During the course of these studies we noted that addition 
of IL-7 to culture medium promoted the long-term growth 
and  maintenance  of antitumor  CTL  in  vitro.  The studies 
presented here were performed to characterize the CTL main- 
tained in vitro for extended periods of time under such con- 
ditions and to evaluate their potential use in the immunother- 
apeutic treatment of cancer. The results dearly demonstrate 
that antitumor CTL can be maintained in vitro for prolonged 
periods of time in the absence of repeated stimulation with 
either tumor-stimulator  cells or tumor antigen.  More im- 
portantly, antitumor CTL propagated in medium containing 
IL-7 retain both their antigenic specificity and their ability 
to reject tumors in vivo subsequent to intravenous injection. 
Materials  and Methods 
Mice.  Female C57BL/10J mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME). Mice were age-matched (10-12-wk- 
old) at the onset of each experiment. 
Tumors.  B10.2 and B10.5 are fibrosarcomas  of B10 origin and 
have been described previously (26, 27). Tumor cell lines were main- 
tained in vitro in c~-modified MEM containing 5% FBS, 2 mM 
glutamine, 50 U/ml penicillin, and 50/~g/ml streptomycin. The 
cultures of tumor cells were routinely screened  for the presence 
of mycoplasma using a detection system (Genprobe, San Diego, 
CA),  and determined to be mycoplasma  free. 
Tumor Immunization and Generation of Antitumor CTL.  Mice 
were injected in the hind footpads with 2-4  x  106 viable  syn- 
geneic tumor cells. DLN were aseptically excised 8-12 d later and 
dissociated into a single cell suspension.  Cell cultures were estab- 
lished (in the absence of added tumor stimulator cells) in upright 
25  cm  2 tissue  culture  flasks  at  1.5  x  106  viable  cells/ml  (20 
ml/flask) in RPMI  1640 medium supplemented with 10% FBS, 
2 mM glutamine,  1 mM sodium pyruvate, 0.1 mM nonessential 
amino acids, 5  x  10 -5 M 2-ME, 50 #g/ml streptomycin, and 50 
U/ml penicillin at 37~  in a humidified atmosphere of 5% CO2 
in air. After 4 d in culture, the resulting CTL were subcultured 
in  24-well  tissue  culture plates  at  a concentration of 5  x  105 
cells/ml (2 ml/well) in medium supplemented with IL-2 (5 ng/ml), 
IL-7 (10 ng/ml),  or a mixture of IL-2 and IL-7 (2 and 10 ng/ml, 
respectively)  with irradiated (10,000 rad) tumor stimulator cells. 
Unless otherwise noted, the subcultures were then maintained by 
weekly feeding with the appropriate medium in the absence of ad- 
ditional tumor cell stimulation.  Cytotoxic activity of CTL was 
determined in a 6-h SlCr-release assay. Percent specific SlCr release 
was calculated as 100  x  [(E -  M)/(NP -  M)], where E  =  cpm 
released in the presence of effector cells, M  =  cpm released in the 
presence of medium alone, and NP = cpm released in the presence 
of 1% NP-40. LU determinations were based on E/T titration curves 
in which one LU was defined as the fraction of the initial culture 
causing 30% lysis of tumor target cells. 
Adoptive Immunotheratry of Tumors In Vivo.  To ensure that the 
anti-tumor immune responses being evaluated were solely due to 
the adoptively transferred cells, recipient mice were irradiated with 
500 rad (using a 137Cs source) to inhibit the generation of primary 
immune responses  (28) and intravenously injected with cultured 
anti-tumor CTL. Mice that received either no cells or cultured lym- 
phocytes obtained from regional LN of normal mice (CLN cells) 
served as controls.  Mice were challenged with 5  x  105 tumor cells 
via intradermal injection in a midline ventral position in a total 
volume of 50/~1. Tumor challenges  were initiated and completed 
within 1 h of the lymphoid cell transfer. Tumor size was calculated 
as the product of two perpendicular diameters of the tumors (as 
measured with calipers),  and is expressed as the mean tumor size 
of all animals  within a particular treatment group. 
Cytokines.  Recombinant murine II_,7 was expressed and purified 
to homogeneity as detailed elsewhere, and had a biological activity 
of 1.4  ￿  105 U/#g protein as determined by its ability to stimu- 
late proliferation of 2B cells (29-31). Recombinant human IL-2 was 
expressed and purified to homogeneity as previously described, and 
had a biological activity of 2.4  x  105 U/~g as determined by its 
ability to stimulate proliferation of CTLL-2 cells (32-34). 
Antibodies.  The monoclonal rat anti-murine I1_,2 Ab $4B6 (35) 
was graciously provided by Tim Mossman (University of Alberta, 
Edmonton, Alberta, Canada). Purified 11Bll Ab (36) was purchased 
from Verax Corp. (Lebanon, NH). FITC-labeled Abs to CD3 (clone 
500A2), CD4 (clone L3T4), CD8 (clone 53-6.7), TCR-c~/j8 (clone 
H57-597), TCR-3,/~ (clone GL-3), LFA-1 (CD11a,  clone 2D7), 
intercellular adhesion molecule (ICAM-1) (clone 3E2), IL-2R ot chain 
(clone 7D4), CD44 (Pgp-1, clone 1M7),  and heat stable antigen 
(HSA) (cloneJlld) were purchased from Pharmingen (San Diego, 
CA). Mel-14 (leukocyte cell adhesion molecule 1) was detected using 
a culture supernatant from the Mel-14 hybridoma (obtained from 
the American Type Culture Collection, Rockville, MD) followed 
by PE-conjugated anti-mouse Ig. 
Immunofluorescent Staining and Flow Cytometry.  500,000 cells 
were preincubated for 30 rain at 4~  with saturating concentra- 
tions of 2.4G2 mAb to block Fc receptors. The cells were washed 
once with PBS containing 0.1% BSA and 0.1% NAN3, and then 
incubated for an additional 30 rain at 4~  with saturating concen- 
trations of the appropriate marker-specific Abs. The cells were then 
washed and analyzed on a FACScan  |  (Becton Dickinson & Co., 
Mountain View, CA) using an argon laser that emitted visible light 
at 488 nm and 15 mW constant power.  Data were collected on 
104 viable  cells and  analyzed using LYSYS II  software (Becton 
Dickinson & Co.). 
Results 
In Vitro and In Vivo Function of Antitumor CTL Propagated 
in Cytokine-containing Medium.  To determine whether an- 
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time in vitro in cytokine-containing media, lymphocytes from 
cultures of B10 anti-B10.5 DLN were recovered and recul- 
tured with irradiated tumor stimulator cells in either medium 
alone or medium containing  IL-2, IL-7,  or a combination 
of IL-2 and IL-7 (106 cells/culture). These cultures were sub- 
sequently passaged every 7-10 d in the appropriate medium 
in the the absence of further stimulation with irradiated  tumor 
cells. Although the numbers of cells in all of the culture groups 
increased  from the initial 106 cells during the first week after 
restimulation,  after 25 d the total number of viable cells re- 
covered from cultures of cells maintained  in medium alone 
had decreased to <3  x  104. The number of cells recovered 
from cultures maintained in IL-2 had increased to 2  x  106 
and cells cultured in IL-7 or IL-2 and IL-7 had increased to 
8  ￿  106 and 11  x  106, respectively.  After the removal of 106 
cells from each of these cultures for assessment of tumori- 
cidal activity in vitro (discussed below), cultures of the re- 
maining cells were maintained in fresh media containing the 
appropriate cytokine(s). After an additional  7 d of culture, 
CTL grown in IL-2 increased from 106 tO 5.6  x  106 cells, 
CTL grown in IL-7 increased from 7.0  x  106 to  17.5  x 
106 cells,  and CTL cultured in a combination of IL-2 and 
IL-7 increased from 10  x  106 to 32  x  106 cells. Thereafter, 
cells from cultures maintained in IL-2 decreased in both total 
number and viability until <(106 were recoverable by day 60 
of culture.  In contrast,  CTL cultured in either  IL-7 alone 
or a combination of IL-2 and IL-7 slowly increased during 
this  time period with  average  doubling  times of 5-6  d. 
Analysis of effector cell function of the CTL maintained 
in vitro for either 25, 32, or 53 d after their initiation demon- 
strated potent and specific tumoricidal activity in vitro (Fig. 
1, A, B, and C,  respectively). Flow cytometric analysis  of 
these three cell populations at day 32 of culture revealed similar 
profiles in which 100%  of the cells were Thy 1.2 +, CD3 + 
T  cells  (Fig.  2).  Of these,  95%  were CD8 + and  ~3-4% 
were CD4 + . 
The ability of these populations of CTL to mediate tumor 
rejection in vivo was initially tested on day 32 of culture by 
intravenously injecting 2  x  10  6 antitumor CTL maintained 
in either IL-7 or IL-2 and IL-7 into 500 rad irradiated recipients, 
followed by bilateral tumor challenge with B10.5 and B10.2 
tumor cells. Recoveries of cells from cultures maintained in 
IL-2 alone were too low to permit functional assessment in 
vivo. Mice that  received anti-B10.5  CTL maintained  in ei- 
ther IL-7 alone or a combination of IL-2 and IL-7 effectively 
rejected challenges orB10.5 tumor cells, but not B10.2 tumor 
cells (Fig. 3 A). Growth of the B10.2 tumor challenge cannot 
be ascribed to an inherent  inability of this tumor to be re- 
jected because B10.2 tumor cells were eliminated by anti-B10.2 
CTL freshly generated from cultures of B10 anti-B10.2 DLN 
cells  (Fig.  3 B). 
During the course of these experiments we noted that the 
tumoricidal activity of the anti-B10.5 CTL slowly decreased 
as a function of increasing time in culture. For example, the 
lyric activity of CTL maintained in IL-2 and IL-7 could not 
be determined at day 25 (because plateau-level killing of target 
cells was observed even at the lowest E/T ratio tested), whereas 
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Figure  1.  Specificity and lytic activity of anti-B10.5 CTL maintained 
in culture by cytokines.  B10 anti-B10.5 CTL that had been maintained 
in continuous  culture  for 25 d (A),  32 d (B), or 53 d (C) by IL-2 (&, 
A), IL-7 (O, C)), or a combination of IL-2 and IL-7 (I,  D) were tested 
using either B10.5 (solid symbols) or B10.2 (open symbols) target  cells. Cytokine(s) used 
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Figure  2.  Flow cytometric analysis of anti-B10.5 CTL maintained in 
continuous culture for 32 d by either IL-2, Ib7, or a combination of IL-2 
and IL-7. (Dashed line) background staining of cells using appropriately 
labeled control Abs. 
at  day 32 there was 29.4 LU/106 cells  and at  day 53  there 
was 19.6 LU/106 cells.  To determine whether restimulation 
of these CTL with irradiated tumor cells would increase their 
cytolytic activity, 5  x  106 effector cells that had been main- 
tained  for 53 d  in medium  containing IL-2 and IL-7 were 
cultured either with or without irradiated B10.5 tumor cells 
and  the  number  and  lytic  activity  of these  CTL  assessed 
4  d  later using either  B10.5  or B10.2  target  cells￿9 Effector 
cells  cultured  in  the  absence of tumor stimulator  cells  in- 
creased  to  7.7  x  106 compared with  15.7  x  106 for cells 
cultured with  tumor stimulator cells.  Cytolytic activity of 
the CTL also increased from 20 to 50 LU/106 cells,  respec- 
tively (Fig.  4). 
Effects of Cytoleines  and Tumor Stimulator Cells on Prolifera- 
tive Responses  ofAntitumor  CTL.  We next sought to deter- 
mine the effect of various cytokines in the presence or ab- 
sence of irradiated tumor stimulator cells on the proliferation 
of CTL grown for 5 mo in vitro￿9 Culture of CTL in medium 
containing IL-2 caused increased levels  of [3H]TdR incorpo- 
ration compared with CTL cultured in the medium alone, 
and substantially increased the levels  of [3H]TdR incorpora- 
tion by the antitumor CTL in the presence of tumor stimu- 
lator cells compared with that induced by tumor stimulator 
cells alone (Table 1). A  slight increase in the proliferative re- 
sponse induced by B10.5 tumor stimulator cells was detected 
in cultures to which IL-4 had been added,  suggesting that 
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Figure 3.  Specificity  and in vivo efficacy  of anti-B10.5 CTL maintained 
in vitro in medium containing 1I,-7. 500 rad-irradiated mice were intrave- 
nously injected with either no cells (O), 6  x  106 cultured CLN (O), 
2  ￿  106 anti-B10.5 CTL maintained for 32 d in IL-7 (F]), or 1I,-2 and 
IL-7 (1), 15  x  106 cultured anti-B10.2 DLN cells (&) or 7.5  ￿  106 cul- 
tured anti-B10.2 DLN cells (A). Mice were then bilaterally challenged 
with B10.5 and B10.2 tumor cells. Growth of the B10.5 (.4) and B10.2 
(B) tumor challenges was monitored over the next 27 d. The number of 
mice bearing B10.5 tumors at the termination of the experiment was: mice 
receiving no cells, 4/4; mice receiving 6  x  106 CLN cells, 4/4; mice 
receiving 2 ￿  106 anti-B10.5 CTL maintained in medium containing Ib7, 
0/4; mice receiving 2 x  106 anti-B10.5 CTL maintained in medium con- 
taining II.-2  and IL-7, 0/4; and mice receiving 15  x  106 anti-B10.2 DLN, 
4/4.  The number of mice bearing B10.2 tumors at the termination of 
the experiment was: mice receiving no cells, 4/4; mice receiving 6 x  106 
CLN cells, 4/4; mice receiving 2  x  106 anti-B10.5 CTL maintained in 
medium containing IL-7, 4/4; mice receiving 2  x  106 anti-B10.5 CTL 
maintained in medium containing I1.-2 and IL-7, 4/4; mice receiving 15 
x  106 anti-B10.2 DLN, 0/4; and mice receiving 7.5  x  106 anti-B10.2 
DLN, 1/4. 
IL-4 could also act as a costimulatory molecule for antigen- 
specific stimulation of these cells. However, no direct stimula- 
tory effect of IL-4 on these CTL was detected and dose-re- 
sponse studies  have indicated  that  the costimulatory effect 
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Figure  4.  Effect of restimulation of anti-B10.5 CTL maintained in 
medium containing IL-2  and IL-7  with irradiated tumor cells on cytolytic 
activity and specificity in vitro. Anti-B10.5 CTL maintained in vitro in 
cytokine-containing  medium were cultured for four additional days in ei- 
ther the absence (ll, l-q) or presence (@, O) of irradiated B10.5 tumor 
cells and cytolytic activity assessed using either B10.5 (solid  symbols) or 
B10.2 (open symbols) target cells. 
of IL-4 is ",50-fold weaker than that mediated by IL-2 (data 
not shown).  None of the other cytokines tested,  including 
IL-7, led to significant increases in proliferation over that seen 
in the presence  of medium  alone. 
In  Vivo Ej~cacy of Antitumor CTL Maintained  in Medium 
Containing  IL-2 and IL-7.  To determine the efficacy of an- 
titumor CTL maintained in culture for extended periods of 
time, CTL that had been maintained in vitro in the absence 
of tumor cell stimulation  for 6 mo were intravenously in- 
jected into 500 rad mice that were intradermally challenged 
with B10.5 tumor cells.  In this experiment,  intravenous in- 
jection of even the lowest number of CTL tested (105) was 
sufficient to mediate complete elimination of the tumor chal- 
Table  1.  Proliferative  Responses of Anti-B10.5  CTL Maintained 
Table  2.  Low Numbers of Anti-B10.5  CTL Maintained in 
IL-7 Effectively Mediate Rejection of Tumors at Distal Skin Sites 
Mean  tumor 
No.  of cells  No.  TBA/  size 
Group  transferred  No.  challenged  (mm  2 _+  SEM) 
A  None*  4/4~  104.5  _+  14.6 
B  3  x  106  0/4  0  _+  0 
C  1  x  106  0/4  0  -+  0 
D  3  x  10  s  0/4  0  _+  0 
E  1  x  105  0/4  0  _+  0 
* Intravenous injection of anti-B10.5 CTL maintained long-term in medi- 
um containing IL-7. 
Number of tumor-bearing animals/number challenged 23 d after in- 
tradermal injection with B10.5 tumor cells. 
lenge (Table 2).  The mice in each of the treatment  groups 
that received the antitumor CTL were monitored for an ad- 
ditional  138 d  after the termination  of the experiment  and 
found to be completely free of detectable  tumors. 
A similar experiment was performed using B10 anti-B10.2 
CTL that had been maintained in vitro for 7 mo in the ab- 
sence of tumor cell restimulation (Fig. 5). In this experiment, 
the intradermal challenge of B10.2 cells  was completely re- 
jected  in  all  mice that  received either  3  x  106  anti-B10.2 
CTL. Although small tumors were detected during the first 
week after  tumor challenge in three of the four mice that 
received 106 CTL,  they were all  found to be tumor free by 
day 13. The tumor challenge also grew transiently in all four 
of the  mice  that  received  3  x  10  s  CTL.  However,  the 
tumors were ultimately rejected in three of the four mice in 
this  group,  and grew more slowly in the 4th mouse com- 
pared with controls. Intravenous injection of 5  x  104 CTL 
proved to be insufficient  to mediate  tumor rejection  since 
in IL-7 to Cytokines and Tumor Stimulator Cells 
Stimulation 
Cytokine 
added  Concentration  None  Irradiated B10.5" 
None  -  1,165.3  _+  248.8~  23,528.6  +_  1,066.4  s 
IL-lot  10 ng/ml  542.0  +  24.0  14,654.0  _+  2,906.1 
IL-2  10 ng/ml  10,004.0  +  379.4  140,550.3  _+  4,904.2 
IL-4  10 ng/ml  1,342.7  _+  147.7  63,098.6  +_  3,806.8 
IL-6  15,000  U  484.0  +  49.2  22,179.3  _+  2,450.0 
IL-7  10 ng/ml  1,955.0  +  511.3  30,215.3  +_  945.5 
IL-2 and IL-7  2 and 10 ng/ml  10,026.0  -+  562.1  127,853.3  +  5,504.7 
* 2,000 rad-irradiated tumor cells. Mean cpm [3H]Tdk incorporation of the irradiated B10.5 tumor cells on day 3 of culture was 5,482  +  1,310. 
* Mean cpm [3H]TdR incorporation  _+  SEM of triplicate wells on day 3 of culture. 
$ Delta cpm [3H]TdR incorporation +  SEM of triplicate wells containing antitumor CTL  +  irradiated tumor cells minus the mean cpm [3H]TdR 
incorporation of irradiated B10.5 cells in medium alone on day 3 of culture. 
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Figure  5.  Low numbers of anti-B10.2  CTL maintained in IL-7 effec- 
tively mediate tumor rejection at distal skin sites. 500 tad-irradiated mice 
were intravenously injected with either no cells (II), 3  x  106 (O),  106 
(l), 3  x  105 (A), or 5  x  104 (0) anti-B10.2 CTL that had been main- 
tained in vitro for 7 mo by passage in medium containing ILo2 and 1I.-7, 
The number of tumor-bearing animals/the number challenged at the ter- 
mination of the experiment was: mice receiving no cells, 4/4; mice receiving 
3  x  106 CTL, 0/4; mice receiving 106 CTL, 0/4; mice receiving 3  x 
10  s CTL,  1/4; and mice receiving 5  x  104 CTL,  4/4. 
progressive tumor growth was observed in all of the mice 
challenged  in  this group. 
Antitumor CTL Maintained Long-Term in Medium Containing 
IL-2 and IL-7 Mediate Tumor Rejection In Vivo.  Although it 
had been determined that CTL cultured for relatively short 
(2-6 mo) periods of time could mediate tumor rejection in 
vivo, it was not known whether this function would be gradu- 
ally lost as a function  of time in culture in the absence of 
specific  stimulation  with  tumor antigen.  Thus,  the ability 
of these CTL to mediate tumor rejection in vivo was tested 
at various times by intravenously injecting  500 rad-irradi- 
ated mice with CTL that had been maintained  under a va- 
riety of conditions followed by an intradermal challenge with 
B10.5 tumor ceUs. antitumor cytotoxic activity of these CTL 
was also measured using a 51Cr-release assay. Not only were 
antitumor CTL from cultures that had been restimulated with 
tumor antigen at various times during their culture history 
able to specifically eliminate a tumor challenge in vivo, but 
so were CTL that  had been maintained  in continuous cul- 
ture in the absence of tumor  stimulation  for as long as 31 
mo (Table 3). The data also demonstrate that cryogenic storage 
of these cells does not result in loss of ability to mediate tumor 
rejection in a systemic fashion.  Interestingly, the in vitro cyto- 
toxic activity of the cell lines  tested was not predictive of 
their  ability to mediate  tumor  rejection in vivo since cells 
without detectable tumoricidal activity in short-term in vitro 
assays were still  able to mediate  tumor rejection  in vivo. 
Proliferation of CTL to Tumor Stimulator Cells Is Dependent 
on Endogenously Produced  IL-2.  The ability of antitumor CTL 
maintained in medium containing IL-2 and IL-7 to proliferate 
in response to stimulation by tumor cells was evaluated by 
culture of these CTL in  the presence of medium  alone or 
irradiated B10.5 tumor cells, in the presence of either $4B6 
(anti-IL-2), 11Bll (anti-IL-4), or a combination of S4B6 and 
11Bll Abs. Proliferative responses of these CTL to stimula- 
tion with B10.5 tumor cells was inhibited with anti-IL-2, 
but not anti-IL-4, Abs (Fig. 6). Nor was the inhibitory effect 
mediated by the anti-IL-2 Abs enhanced by addition of anti- 
IL-4 Abs. Thus, the proliferative responses induced in these 
CTL are dependent upon endogenously produced IL-2. Fur- 
ther, although IL-4 can act as a cofactor to promote prolifer- 
ative responses induced by tumor-stimulator  cells, its pres- 
ence is neither  required  nor  sufficient. 
Kinetics of Cytokine Production after Stimulation with Tumor 
Cells In  Vitro.  Anti-B10.5  CTL maintained  in culture for 
23 mo in medium containing  IL-2 and IL-7 were cultured 
either alone or with irradiated B10.5 or B10.2 stimulator cells. 
Culture supernatants from replicate wells were harvested 24, 
48, 72, or 96 h after culture initiation.  Analysis of cytokines 
present in the supernatants revealed significant levels of IL-2 
produced by CTL stimulated with B10.5 tumor cells during 
the first 24 h (Fig.  7 A). Lower levels of IL-2 were also de- 
tected in supernatants collected after 48 h of culture, but not 
after 72 or 96 h,  suggesting that  the IL-2 being produced 
was also being consumed by the CTL.  This interpretation 
is consistent with the finding that anti-IL-2 Abs completely 
inhibited the proliferative response of the CTL to B10.5 stimu- 
lator cells. The possibility that the IL-2 detected in these su- 
pernatants  was produced by CD4 + cells  is not  supported 
since no CD4 + cells could be detected by FACS  |  analysis. 
Nor was IL-2 detected in supernatants from CTL cultured 
either in medium  alone or with B10.2 stimulator  cells. 
High levels of IFN-y were also produced by the CTL after 
stimulation with B10.5, but not B10.2, tumor cells (Fig.  7 
B). In contrast to the situation observed with IL-2 produc- 
tion,  however, the levels of IFN-9/detected remained  rela- 
tively high throughout the course of the experiment. Thus, 
either the IFN-9/produced was not consumed to any significant 
degree by the CTL or the CTL continued to produce this 
cytokine for extended periods of time after stimulation with 
the B10.5 tumor cells. As with IL-2, no production of IFN-9/ 
was detected in cultures of CTL cultured with B10.2 tumor 
cells or in medium alone. No IL-4 or TNF-oe was detected 
in supernatants from CTL cultured with either B10.5 or B10.2 
stimulator  cells  at any of the  time points  tested. 
Flow Cytometric Analysis of  Antitumor CTL Maintained Long- 
Term in Medium Containing 11_.-7.  Flow microfluorometric 
analysis of anti-B10.5 CTL maintained for 22 mo in medium 
containing  IL-2  and  IL-7  determined  them  to  be 
CD3+4-8 + T  cells  expressing TCR-oe/3,  but  not  TCR- 
9//8,  receptors  (Fig.  8).  These  CTL  also  express  CD-44, 
ICAM-1, LFA-1, and Mel-14, but not HSA, cell surface de- 
terminants.  Low levels of IL-2R (a chain) were also found 
to be expressed by the majority of these cells. Thus, the data 
regarding the cell surface phenotype of the antitumor CTL 
maintained  in medium containing IL-7 are consistent with 
these cells being mature memory cells with the ability to traffic 
through,  and extravasate from, the vasculature at the site of 
a tumor challenge. 
Elimination of  Established Tumors by CTL Maintained In Vitro 
in Medium Containing IL-7.  Finally,  to determine whether 
36  IL-7 Promotes Long-Term  Growth of Antitumor CTL In Vitro Table  3.  Anti-B10.5  CTL  Maintained In  Vitro for Extended Periods of Time in Medium  Containing IL-7 Mediate 
Specific Tumor Rejection In  Vivo 
Tumor  challenge 
B10.5 
Mean  tumor 
Cells  LUa0/  No.  TBA/  size  No.  TBA/ 
Expt.  injected*  Culture  history  106 cells  no.  chalt  (mm  ~ _+  SEM)  No.  chal* 
B10.2 
Mean  tumor 
size 
(mm  2  _+  SEM) 
lS  None  -  -  5/5  139.9  _+  33.7  5/5 
o~B10.5  CTL  Continuous,  11.5  mo  <0.1  0/5  0  -+  0  5/5 
c~B10.5  CTL  Continuous,  11.5  mo  <0.1  0/5  0  +  0  5/5 
Restimulated  i  x  @  2  mo. 
o~B10.5  CTL  Frozen  @  2  mo  40.8  0/5  0  +  0  5/5 
Liquid  N2  storage,  9  mo 
Restimulated  1 x  @  thaw 
Cultured  12 d 
None  -  -  5/5  67.9  _+  15.9  NTII 
o~B10.5  CTL  Continuous,  17 mo  15.4  0/5  0  -+  0  NT 
c~B10.5  CTL  Continuous,  17  mo  <0.1  0/5  0  -+  0  NT 
Restimulated  1 x  @  2  mo 
c~B10.5  CTL  Frozen  @  2  mo  39.6  0/5  0  _+  0  NT 
Liquid  N2,  9  mo 
Restimulated  1 x  @  thaw 
Continuous,  6  mo 
None  -  -  5/5  58.1  _+  8.5  NT 
c~B10.5  CTL  Continuous,  31  mo  NT  1/5  7.2  _+  1.4  NT 
162.9  +  10.5 
172.3  -+  28.7 
170.0  +  43.7 
226.7  _+  15.6 
* The number of CTL  injected into each recipient IV was  106 (Expt.  1),  2  x  106 (Expt.  2). 
* Number of tumor-bearing animals/number challenged at the termination of the experiment. The observation periods for the three experiments 
reported were 30,  31,  and 27 d,  respectively. 
S Mice were bilaterally challenged with both B10.5  and B10.2 tumor cells by intradermal injection. 
II Not tested. 
L 
$4B6 + 11 Bll  L~ 
(an,~.iL-2 § en,-,'-4l f~i~t 
I  I 
o 
"o  [~i~-~-!  ~':'-!  ~~  ~  ~I  Stimulator Cells  ID 
<  $4B6  None 
(anti-lL-2) [~...g}~}~ 
'~'~  I ~''~''~':~:a  []  Irrad. B10.5 
<  11Bll  ~  /r 
(anti-lL-4) r~,,.-~.~.~.~  .~~~.~[.~.~i~i.~ 
I  I  I  .~,  I  I  I  I  I  I  I 
2000  4000  28000  32000  36000  40000 
CPM 3H-TdR Incorporation 
37  Lynch and Miller 
Figure  6.  Proliferation of anti-B10.5  CTL  to 
tumor  stimulator  cells  is  dependent  upon  en- 
dogenously produced IL-2. Anti-B10.5 CTL that 
had been maintained in vitro in medium containing 
a combination of 11.-2 and II.-7 were cultured ei- 
ther in medium alone (hatched bars) or with irradi- 
ated B10.5 tumor cells (stippled bars) in either the 
absence or presence  of anti-IL-2  and/or anti-IL-4 
Abs, as indicated.  Proliferation was  assessed by 
[aH]thymidine incorporation 48 h  after culture 
initiation. A 
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Figure  7.  Kinetics  of cytokine 
production by CTL after stimula- 
tion  with  irradiated  tumor  cells. 
Anti-B10.5  CTL  that  had  been 
maintained in vitro in medium con- 
taining IL-2 and I1.-7 were cultured 
either in medium alone, or with ir- 
radiated B10.2 or B10.5 tumor cells, 
as indicated.  Culture supernatants 
from replicate wells were harvested 
24, 48,  72,  and 96 h after culture 
initiation and assayed for cytokine 
activity. 
antitumor CTL maintained in vitro in medium containing 
IL-7 could be used to immunotherapeuticaUy eliminate es- 
tablished tumors in vivo, tumors were established in groups 
of mice by intradermal  injection with 5  x  105 B10.5 tumors 
cells before adoptive transfer with antitumor CTL. 3 d after 
tumor  challenge,  the  mean  size  of the  tumors  was  ~11 
mmL  On the fourth day after  tumor challenge,  groups of 
mice received either no cells  or 3  x  106,  106, or 5  x  105 
anti-B10.5 CTL. The CTL used in this experiment had been 
maintained in continuous culture in medium containing IL-7 
for 11 too, and then had been cryogenically stored for 33 mo 
in liquid nitrogen. Before use in this experiment,  the CTL 
were thawed and cultured for an additional 2 mo in medium 
containing IL-2 and IL-7. The tumor challenges were com- 
pletely rejected  in 75% of the mice that received  either 3  x 
106 or  106 CTL  (Fig.  9).  Mice that received only 5  x  105 
CTL continued to grow the tumor challenge, but at a slower 
rate than control mice that received no CTL. Thus, antitumor 
CTL  maintained in vitro  for extended periods of time in 
medium containing IL-7 are also capable  of eliminating es- 
tablished tumors in vivo. 
Discussion 
The studies presented here were conducted to determine 
whether IL-7 could promote the long-term growth of an- 
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Figure 8.  Flow  cytometric analysis of anti-B10.5 CTL maintained for 
22 mo in medium containing IL-2 and IL-7. (Dashed lines) background 
staining of cells using appropriately labeled control Abs. 
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Figure  9.  Antitumor CTL  maintained in  medium  containing II.-7 
mediate rejection of established tumors in vivo. Tumors were established 
in 500 tad-irradiated mice by intradermal injection with 5  x  10  s B10.5 
tumor cells 4 d before intravenous injection with either no cells (I)  or 
3  x  106 (A),106 (O), or 5  x  l0  s (A) CTL. The CTL used in this ex- 
periment had been maintained in continuous culture in medium containing 
IL-2 and IL-7 for 11 mo followed  by cryogenic storage for 33 mo.  The 
CTL were thawed and cultured for an additional 2 mo in medium con- 
taining IL-2 and IL-7 immediately before use in this experiment. The number 
of tumor-bearing animals/the number challenged at the termination of 
the experiment was: mice receiving no cells, 4/4; mice receiving 3  x  106 
CTL,  1/4; mice receiving 106 CTL,  1/4; and mice receiving 5  x  10  s 
CTL,  4/4. 
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titumor CTL in vitro. The results not only demonstrate that 
tumor-specific CTL can be maintained in vitro in IL-7, but 
that  repeated restimulation  of the cells is not necessary for 
their maintenance.  Parallel cultures of antitumor CTL simi- 
larly cultured in medium containing  only IL-2 could only 
be maintained  for 5-6 wk, after which the number and propor- 
tion of viable cells that were recoverable from such cultures 
progressively decreased.  In contrast,  cell cultured in either 
IL-7 or a combination of IL-2 and IL-7 grew at a slower pace, 
yet cell viability remained  consistently high  (>98%).  Fur- 
ther, these CTL maintained  the ability to specifically proliferate 
upon stimulation with tumor cells.  More importantly,  the 
effector cells were able to effectively reject tumor challenges 
in vivo in  a systemic fashion after intravenous  injection. 
The lytic activity of antitumor  CTL maintained  in cul- 
ture with IL-7  was found to slowly decrease as a function 
of increasing time in culture. Although the reasons for this 
phenomenon  are not  understood,  a substantial  increase in 
tumoricidal activity was detected after a short in vitro restimu- 
lation of the CTL with tumor cells  (Fig.  4).  The in vitro 
cytolytic activity of CTL cultured for extended periods of 
time (i.e., 11-31 mo) was also found to be somewhat variable 
(Table 3). However, the data also clearly indicate that the cyto- 
lytic activity of effector cell populations cannot be used as 
reliable predictors of in vivo ef~cacy, since cells with no ap- 
parent cytotoxic activity (as measured in a short-term SlCr- 
release  assay) were still able to mediate tumor rejection in 
vivo. This  observation is in agreement with  the results of 
previous studies by both ourselves (27) and others (21) who 
have demonstrated that in vitro assays of tumoricidal activity 
cannot be used as reliable predictors of therapeutic  activity 
in vivo. 
Early in their culture history (ca 6 wk) a small percentage 
of the  ceils  were  found  to  be  CD4 +,  although  the  vast 
majority (95%) were identified as CD8 + T  ceils.  This led 
to the early speculation that the CD4 + T  cells might actu- 
ally be tumor-specific helper cells that were required to pro- 
mote the propagation of the antitumor CTL. However, pheno- 
typic analysis of the CTL after extended culture (i.e., 22 too) 
demonstrated  them  to be uniformly  CD3+4-8 +  T  cells. 
These cells were also found to express LFA-1, ICAM-1, and 
Mel-14  cell interaction  molecules.  These  determinants  no 
doubt play an integral role in the ability of the CTL to traf~c 
through the circulation to the site of an intradermal  tumor 
challenge  to mediate tumor rejection. 
It is also of interest to note that these CTL do not require 
the presence of APC populations to process and present tumor 
antigen  to the CTL,  indicating  that  the CTL recognize a 
tumor-specific antigen on the surface of the tumor ceils them- 
selves. Whether the tumor antigen is processed in some way 
by the tumor cells is not known.  However, recognition of 
the tumor antigen by the CTL is most likely restricted by 
MHC class I determinants,  since both proliferative and cyto- 
toxic responses are inhibited by anti-CD8, but not anti-CD4, 
mAbs (our unpublished  observations). 
The anti-B10.5 CTL maintained long-term in medium con- 
taining IL-2 and IL-7 also express low levels of IL-2R.. Al- 
though the CTL do not require the addition of exogenous IL-2 to survive in vivo, it is clear that they require the pres- 
ence of this cytokine to proliferate in response to tumor stimu- 
lator cells  (Fig.  6).  Similar results  have also been obtained 
using CTL maintained in IL-7 alone (data not shown). The 
data  also  demonstrate  that  the  cells  in  these  cultures  en- 
dogenously produce sufficient quantities of IL-2 for this pur- 
pose. Thus, these CTL have become independent of the re- 
quirement  for CD4 §  helper  cells to  survive and  function 
either in vitro or in vivo. Cells in these cultures also produce 
IFN-y in response to stimulation with tumor cells in vitro. 
However, preliminary studies indicate that IFN-y is not re- 
quired for either proliferative or cytotoxic responses of these 
effector cells to tumors (data not shown). Whether the secre- 
tion of IFN-3' in vivo plays a significant role in tumor rejec- 
tion  is not  known  at  this  time. 
The existence of helper-independent  antitumor  CTL has 
been described previously (37). However, these cells not only 
required clonal activation before use, but also required ancil- 
lary IL-2 treatment of the recipients subsequent to adoptive 
transfer in order to demonstrate therapeutic efficacy (21). Such 
manipulations were not required to demonstrate tumor elimi- 
nation  in vivo by the antitumor  CTL described here. 
Although no attempt was made to clone the tumor-reactive 
T  cells  in  these experiments,  it  seems highly  likely that  a 
significant  selection for such cells  has occurred.  In this re- 
gard, it is somewhat surprising that continued culture of het- 
erogeneous starting populations of lymphoid cells containing 
antitumor CTL in medium containing IL-7 tended to favor 
the outgrowth  of effector cells  that  retained  the ability to 
mediate tumor rejection in vivo.  This  should  not be con- 
strued to mean that IL-7 necessarily selects for cell lines which 
will function in vivo. A more likely explanation is that IL-7 
promotes the survival and slow growth of specifically  acti- 
vated T cells, and a high proportion of antitumor CTL gener- 
ated from DLN are capable of functioning  in vivo. 
The potential implications of the results of this study for 
the immunotherapeutic treatment of cancer may be significant. 
To date,  most adoptive immunotherapy  trials have focused 
on the generation of extremely large numbers of tumoricidal 
cells. Methods that have been used to achieve this goal have 
included intermittent stimulation of lymphoid cells obtained 
from hyperimmunized donors with tumor cells or tumor an- 
tigen (6, 37, 38), nonspecific propagation with IL-2 (14-16), 
combinations of these two approaches (7-9, 20), or nonspecific 
stimulation with Ab to CD3 in combination with IL-2 (39, 
40). Each of these approaches has attendant problems which 
have prevented them from being widely applicable to the im- 
munotherapy of malignancy. For example, intermittent stim- 
ulation with tumor cells suffers from the problem that cells 
from spontaneously arising tumors are often difficult to prop- 
agate in vitro. Further, flesh tumors may contain infiltrating 
suppressor cells or may themselves produce suppressive factors 
(such as TGF-3). Expansion of tumoricidal lymphocytes with 
IL-2 (either alone or in combination with intermittent  stim- 
ulation with tumor cells)  tends to lead to the development 
ofT ceils dependent on exogenous IL-2 for continued growth 
and survival,  both in vitro or in vivo (6,  38,  41).  Finally, 
tumor-reactive T  cells propagated with anti-CD3  and IL-2 
show  progressive  decreases  in  both  in  vitro  and  in  vivo 
antitumor reactivity with repeated cycles of stimulation (38). 
In contrast, the results of the studies presented here demon- 
strate that IL-7 promotes not only the propagation and main- 
tenance of antitumor  CTL for extended periods of time in 
vitro in the absence of repeated stimulation with either tumor 
cells or tumor antigen, but promotes the retention of in vivo 
function  as well. 
Data  presented  here  demonstrate  that  antitumor  CTL 
specific for tumors induced by either chronic exposure to UV 
irradiation  (B10.5)  or by the chemical carcinogen  methyl- 
cholanthrene (B10.2) can be propagated in culture for extended 
periods of time using IL-7.  In these experiments,  we used 
antitumor  CTL generated in vitro from the DLN of mice 
injected with viable syngeneic tumor cells. These cells were 
subsequently restimulated one time in vitro with irradiated 
tumor cells in medium containing  IL-2, IL-7,  or IL-2 and 
IL-7.  However, the in vitro restimulation  does not appear 
to be strictly required  for the generation  and maintenance 
of tumor-reactive cell lines since similar results have also been 
obtained using cultures of CTL generated from DLN in the 
absence of restimulation with tumor cells in vitro (our un- 
published observations). Nor are the beneficial effects medi- 
ated  by  IL-7  necessarily  limited  to  CD8 +  T  cells,  since 
antigen-specific  CD4 +  cells  have  also  been  found  to  be 
maintained for extended periods of time (ca 12 too) in IL-7. 
It is also interesting to note that although short-term culture 
of heterogeneous populations oflymphocytes from both mouse 
and humans  in IL-7 promotes the generation of LAK (42, 
43), such nonantigen-specific effector cells did not continue 
to proliferate in long-term cultures supplemented with IL-7. 
Indeed,  after 4-5 wk of culture,  only tumor-specific CTL 
continued to be maintained in cultures containing IL-7. The 
reasons for this phenomenon are not known, but have also 
been observed in populations of CTL maintained in IL-2 (38 
and Fig.  1). 
In conclusion, data presented here demonstrate that specific, 
antitumor CTL capable of mediating tumor rejection in vivo 
can be maintained  in vitro for extended periods of time in 
the absence of repeated stimulation  with  irradiated  tumor 
cells. Thus, with a continuously available source of antitumor 
effector cells,  individuals  with  tumors could be treated  (if 
need be) with several courses of CTL infusion. Further, with 
the increased specificity of the effector cell populations due 
to the absence of LAK activity, it  seems likely that  fewer 
cells might need to be infused compared with protocols cur- 
rently in clinical  use. Third,  these cells can be cryogenically 
stored with  no apparent  loss in activity. Finally,  such cells 
do not require the recipients to be treated with exogenous 
cytokines to promote or maintain  function in vivo. Given 
the range of toxicities found to be caused by IL-2 administra- 
tion  in  humans  (44),  avoidance of IL-2  therapy might  be 
beneficial.  Since IL-7 promotes many, if not all, of the same 
biological activities in both mouse and human,  the use of 
IL-7 to beneficially augment the generation and propagation 
of antitumor  CTL  may  have  profound  implications  for 
promoting the immunotherapeutic treatment of neoplasia in 
cancer patients. 
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